Company intelligence / Profile preview

Libra Pixel

San Diego, California, United Stateslibrapixel.com ↗

Ownership: Private
Development stage: Other

Overview

Libra Therapeutics' lead small molecule program targets TRPML1 to enhance lysosomal function and protein clearance, aiming to halt or slow neurodegeneration. The lead candidate is in IND-enabling studies with Phase 1 trials planned for 2025. Two additional programs are at the target validation/discovery stage.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Multiple international CROs including Axxam; no major pharma partnerships publicly listed as of June 2025.

Beyond the preview

Go deeper on Libra Pixel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Pixel.

Explore the full profile